Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for SPRY

Stock NameSilverback Therapeutics Inc
TickerSPRY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS82835W1080

Show aggregate SPRY holdings

News associated with SPRY

XTX Topco Ltd Grows Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
XTX Topco Ltd grew its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 54.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,647 shares of the company’s stock after buying an additional 17,429 shares during the period. XTX Topco Ltd’s holdings in […] - 2025-08-06 05:18:53
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus PT from Brokerages
Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) have received a consensus rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year […] - 2025-07-14 02:56:47
Oppenheimer & Co. Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Oppenheimer & Co. Inc. purchased a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the 1st quarter, Holdings Channel reports. The firm purchased 15,014 shares of the company’s stock, valued at approximately $189,000. Other large investors have also modified their holdings of the company. Wellington Management Group LLP boosted its position in […] - 2025-07-04 04:36:46
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder Sells 740,149 Shares of Stock
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) major shareholder James E. Flynn sold 740,149 shares of the business’s stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $18.46, for a total value of $13,663,150.54. Following the completion of the transaction, the insider directly owned 4,887,254 shares […] - 2025-07-03 05:26:53
ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded to “Hold” at Wall Street Zen
Wall Street Zen upgraded shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning. A number of other brokerages have also recently commented on SPRY. Scotiabank initiated coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set […] - 2025-06-29 05:18:51
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target […] - 2025-06-19 02:46:58
Wellington Management Group LLP Buys 917 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Wellington Management Group LLP raised its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 0.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 163,252 shares of the company’s stock after purchasing an additional 917 shares during the period. Wellington Management Group LLP’s holdings in ARS Pharmaceuticals were worth $1,722,000 as of […] - 2025-06-06 06:12:51
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by Deutsche Bank AG
Deutsche Bank AG increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 50.8% in the fourth quarter, Holdings Channel reports. The firm owned 43,377 shares of the company’s stock after purchasing an additional 14,604 shares during the period. Deutsche Bank AG’s holdings in ARS Pharmaceuticals were worth $458,000 as of its most […] - 2025-05-30 04:46:50
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Northern Trust Corp
Northern Trust Corp lifted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 5.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 478,153 shares of the company’s stock after acquiring an additional 25,773 shares during the period. Northern Trust Corp’s holdings in ARS Pharmaceuticals were worth $5,045,000 as of […] - 2025-05-22 04:20:52
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Position Boosted by Wells Fargo & Company MN
Wells Fargo & Company MN lifted its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 47.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 41,701 shares of the company’s stock after acquiring an additional 13,361 shares during the quarter. Wells Fargo & Company MN’s holdings in ARS Pharmaceuticals were worth $440,000 […] - 2025-05-05 05:00:50
Brokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month […] - 2025-04-30 02:10:55
Raymond James Financial Inc. Takes $6.58 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Raymond James Financial Inc. purchased a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other institutional investors have also made […] - 2025-04-24 06:31:08
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,002 Shares
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) Director Laura Shawver sold 50,002 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total transaction of $615,024.60. Following the sale, the director now owns 210,346 shares of the company’s […] - 2025-04-10 05:12:56
Intech Investment Management LLC Has $322,000 Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Intech Investment Management LLC lifted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 85.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 30,545 shares of the company’s stock after buying an additional 14,051 shares during the quarter. Intech Investment […] - 2025-03-26 07:16:48
Raymond James Financial Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Raymond James Financial Inc. purchased a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the fourth quarter, HoldingsChannel reports. The fund purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other large investors also recently added to or reduced their stakes in the company. Compass Capital Corp MA ADV purchased […] - 2025-03-24 05:50:52
Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY)
Scotiabank began coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a report released on Friday, MarketBeat.com reports. The firm issued a sector outperform rating and a $30.00 target price on the stock. SPRY has been the subject of several other research reports. Raymond James lifted their target price on ARS Pharmaceuticals from […] - 2025-03-10 03:50:50
Allspring Global Investments Holdings LLC Buys 165,950 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Allspring Global Investments Holdings LLC increased its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 93.1% during the 4th quarter, Holdings Channel reports. The fund owned 344,171 shares of the company’s stock after acquiring an additional 165,950 shares during the period. Allspring Global Investments Holdings LLC’s holdings in ARS Pharmaceuticals were […] - 2025-02-21 06:12:48

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) SPRY holdings

DateNumber of SPRY Shares HeldBase Market Value of SPRY SharesLocal Market Value of SPRY SharesChange in SPRY Shares HeldChange in SPRY Base ValueCurrent Price per SPRY Share HeldPrevious Price per SPRY Share Held
2025-11-11 (Tuesday)62,782USD 550,598USD 550,598
2025-11-10 (Monday)62,782SPRY holding increased by 162USD 557,504SPRY holding increased by 3317USD 557,504162USD 3,317 USD 8.88 USD 8.85
2025-11-07 (Friday)62,620USD 554,187SPRY holding increased by 41016USD 554,1870USD 41,016 USD 8.85 USD 8.195
2025-11-06 (Thursday)62,620SPRY holding increased by 162USD 513,171SPRY holding decreased by -52074USD 513,171162USD -52,074 USD 8.195 USD 9.05
2025-11-05 (Wednesday)62,458USD 565,245SPRY holding increased by 21236USD 565,2450USD 21,236 USD 9.05 USD 8.71
2025-11-04 (Tuesday)62,458SPRY holding increased by 163USD 544,009SPRY holding increased by 7026USD 544,009163USD 7,026 USD 8.71 USD 8.62
2025-11-03 (Monday)62,295USD 536,983SPRY holding decreased by -21180USD 536,9830USD -21,180 USD 8.62 USD 8.96
2025-10-31 (Friday)62,295USD 558,163SPRY holding increased by 21180USD 558,1630USD 21,180 USD 8.96 USD 8.62
2025-10-30 (Thursday)62,295SPRY holding increased by 815USD 536,983SPRY holding decreased by -15107USD 536,983815USD -15,107 USD 8.62 USD 8.97999
2025-10-29 (Wednesday)61,480SPRY holding increased by 326USD 552,090SPRY holding decreased by -22146USD 552,090326USD -22,146 USD 8.97999 USD 9.39
2025-10-28 (Tuesday)61,154USD 574,236SPRY holding decreased by -10396USD 574,2360USD -10,396 USD 9.39 USD 9.56
2025-10-27 (Monday)61,154USD 584,632SPRY holding increased by 27519USD 584,6320USD 27,519 USD 9.56 USD 9.11
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SPRY by Blackrock for IE00BYXG2H39

Show aggregate share trades of SPRY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY162 8.880* 13.44
2025-11-06BUY162 8.195* 13.49
2025-11-04BUY163 8.710* 13.54
2025-10-30BUY8159.0008.590 8.631USD 7,034 13.61
2025-10-29BUY3268.9809.460 9.412USD 3,068 13.64
2025-10-22SELL-6489.7209.940 9.918USD -6,427 13.75 Profit of 2,482 on sale
2025-10-20BUY32410.01010.375 10.339USD 3,350 13.79
2025-10-17BUY80910.05010.170 10.158USD 8,218 13.81
2025-10-15BUY1,28810.97011.060 11.051USD 14,234 13.83
2025-10-03BUY1,14110.31011.030 10.958USD 12,503 13.86
2025-10-02BUY16310.28010.500 10.478USD 1,708 13.88
2025-09-30BUY32610.05010.400 10.365USD 3,379 13.93
2025-09-26BUY3269.8009.925 9.913USD 3,231 13.98
2025-09-25BUY3269.5409.700 9.684USD 3,157 14.00
2025-09-24SELL-3,0619.6309.990 9.954USD -30,469 14.03 Profit of 12,466 on sale
2025-09-18BUY1739.9309.980 9.975USD 1,726 14.05
2025-09-17BUY5199.5709.800 9.777USD 5,074 14.08
2025-08-20SELL-68414.60014.740 14.726USD -10,073 14.11 Loss of -420 on sale
2025-07-30BUY68017.88018.415 18.362USD 12,486 14.04
2025-07-17SELL-34018.35018.440 18.431USD -6,267 13.81 Loss of -1,573 on sale
2025-07-16BUY1,58417.87017.990 17.978USD 28,477 13.78
2025-07-11SELL-1,32817.69018.045 18.010USD -23,917 13.70 Loss of -5,726 on sale
2025-07-07BUY49817.09017.900 17.819USD 8,874 13.59
2025-07-02BUY9,13016.75016.760 16.759USD 153,010 13.55
2025-06-11BUY33414.34014.800 14.754USD 4,928 13.45
2025-06-10BUY33414.69014.780 14.771USD 4,934 13.44
2025-06-04SELL-16713.82014.700 14.612USD -2,440 13.42 Loss of -199 on sale
2025-04-23BUY16614.38015.440 15.334USD 2,545 13.22
2025-04-10SELL-1,32813.24013.663 13.621USD -18,088 13.09 Loss of -710 on sale
2025-04-08SELL-16612.33013.420 13.311USD -2,210 13.09 Loss of -36 on sale
2025-04-07SELL-16612.83013.785 13.689USD -2,272 13.10 Loss of -99 on sale
2025-04-04SELL-83512.80013.730 13.637USD -11,387 13.10 Loss of -450 on sale
2025-04-01BUY2,48012.53012.850 12.818USD 31,789 13.11
2025-03-31SELL-48312.58012.770 12.751USD -6,159 13.11 Profit of 175 on sale
2025-03-21BUY2,10912.36014.250 14.061USD 29,655 13.15
2025-03-14SELL-2,48011.87012.255 12.217USD -30,297 13.22 Profit of 2,478 on sale
2025-03-07SELL-31010.85011.160 11.129USD -3,450 13.35 Profit of 687 on sale
2025-03-04SELL-15510.51010.720 10.699USD -1,658 13.47 Profit of 430 on sale
2025-02-25BUY31010.56010.980 10.938USD 3,391 13.74
2025-02-19SELL-15412.00012.020 12.018USD -1,851 13.91 Profit of 291 on sale
2025-02-13BUY46211.92012.010 12.001USD 5,544 14.07
2025-02-12BUY15411.63011.770 11.756USD 1,810 14.12
2025-02-11BUY61611.55012.030 11.982USD 7,381 14.17
2024-12-30SELL-4,73710.62010.690 10.683USD -50,605 14.73 Profit of 19,151 on sale
2024-11-18SELL-2,49013.78014.370 14.311USD -35,634 15.64 Profit of 3,298 on sale
2024-11-08SELL-16617.04017.070 17.067USD -2,833 15.47 Loss of -266 on sale
2024-10-21SELL-16616.72016.750 16.747USD -2,780 0.00 Loss of -2,780 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SPRY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-191,036,8112,3391,919,45054.0%
2025-09-18517,1502,816987,03052.4%
2025-09-17379,1150772,88949.1%
2025-09-16623,4913,7001,009,54061.8%
2025-09-15663,2712,9001,595,65241.6%
2025-09-12577,30001,228,78147.0%
2025-09-11685,503145,2731,124,46461.0%
2025-09-10556,3710984,01356.5%
2025-09-09453,1620963,62047.0%
2025-09-08859,020224,3582,428,49835.4%
2025-09-05832,45076,2002,588,10832.2%
2025-09-04957,84722,3602,125,95345.1%
2025-09-03766,34802,155,07335.6%
2025-09-02861,44211,8872,040,77442.2%
2025-08-291,336,171183,2053,462,65338.6%
2025-08-28547,9091,1251,082,19550.6%
2025-08-27412,301500704,46958.5%
2025-08-26553,1462,580775,64771.3%
2025-08-25615,80301,289,82947.7%
2025-08-221,207,2606011,546,06378.1%
2025-08-21468,22250,536608,42677.0%
2025-08-20671,67926,4411,106,64560.7%
2025-08-19623,9808,7351,160,28653.8%
2025-08-18382,3561,900673,95556.7%
2025-08-15844,0747251,153,24173.2%
2025-08-141,133,77822,5001,427,33779.4%
2025-08-131,127,52239,0661,770,07163.7%
2025-08-12787,9130995,28579.2%
2025-08-11351,430640901,14139.0%
2025-08-08132,6850238,49755.6%
2025-08-07164,5939,579265,41462.0%
2025-08-06240,878103378,52363.6%
2025-08-05192,0660313,29961.3%
2025-08-04293,4729,962499,57358.7%
2025-08-01429,2560556,08277.2%
2025-07-31291,6240421,55269.2%
2025-07-30232,3150483,32548.1%
2025-07-29172,573430276,47762.4%
2025-07-28529,66801,110,31647.7%
2025-07-25643,37801,004,27664.1%
2025-07-24275,4420656,20742.0%
2025-07-23235,4660569,67141.3%
2025-07-22197,9120274,37472.1%
2025-07-21184,0000266,53069.0%
2025-07-18349,9760556,77162.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.